Mechanism of Selective Inhibition of Respiratory Syncytial Virus by a Benzodithiin Compound (RD3–0028)

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Microbiology and immunology

• Publication date

  2001-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1348-0421.2001.tb02654.xPMID 11529559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

  1998cited by this paper
• Novel anti-respiratory syncytial(RS) viral compounds: benzodithiin derivatives.

  1998cited by this paper
• Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.

  1998cited by this paper
• Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells.

  1997cited by this paper
• Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.

  1996cited by this paper
• Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus.

  1996cited by this paper
• Efficacy of RD3-0028 Aerosol Treatment against Respiratory Syncytial Virus Infection in Immunosuppressed Mice

  1996cited by this paper
• In vitro Antimyxovirus and Anti-Human Immunodeficiency Virus Activities of Polyoxometalates

  1995cited by this paper
• Antiviral Activities of Peptides with Sequences Related to the Cytoplasmic Domain of the Respiratory Syncytial Virus Glycoproteins

  1995cited by this paper
• Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.

  1995cited by this paper
• MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents.

  1994cited by this paper
• Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.

  1994cited by this paper
• Prospects for a respiratory syncytial virus vaccine.

  1994cited by this paper
• In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion

  1994cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

  1993cited by this paper
• Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection

  1993cited by this paper
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

  1993cited by this paper
• Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses

  1992cited by this paper
• Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.

  1992cited by this paper
• New neplanocin analogues. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum antiviral agents.

  1992cited by this paper
• Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

  1991cited by this paper
• Progress towards control of the acute respiratory viral diseases of childhood.

  1987cited by this paper
• Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus

  1987cited by this paper
• Progress towards control of the acute respiratory viral diseases of childhood.

  1987cited by this paper
• Conformational change in a viral glycoprotein during maturation due to disulfide bond disruption.

  1987cited by this paper
• Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies.

  1986cited by this paper
• Kinetics of synthesis of respiratory syncytial virus glycoproteins.

  1985cited by this paper
• Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

  1985cited by this paper
• Conformational changes in Newcastle disease virus fusion glycoprotein during intracellular transport

  1985cited by this paper
• Respiratory syncytial virus polypeptides. V. The kinetics of glycoprotein synthesis.

  1985cited by this paper
• Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

  1984cited by this paper

• Exploring the secrets of virus entry: the first respiratory syncytial virus carrying beta lactamase

  2024cites this paper
• Potential anti-respiratory syncytial virus lead compounds from Aglaia species.

  2008cites this paper
• Development of Antivirals against Respiratory Syncytial Virus

  2006cites this paper
• Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function

  2006cites this paper
• Antiviral activity and mode of action of caffeoylquinic acids from Schefflera heptaphylla (L.) Frodin.

  2005cites this paper
• Antisense approaches for inhibiting respiratory syncytial virus

  2005influential citation
• Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection

  2004cites this paper
• Orally Active Fusion Inhibitor of Respiratory Syncytial Virus

  2004cites this paper
• Animal Pneumoviruses: Molecular Genetics and Pathogenesis

  2004cites this paper
• Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus.

  2004cites this paper
• Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what’s in the pipeline?

  2004cites this paper
• In search of a small-molecule inhibitor for respiratory syncytial virus

  2004cites this paper
• Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion.

  2003cites this paper
• Chapter 14. Antiviral agents

  2002cites this paper
• The Quest for an Efficacious Antiviral for Respiratory Syncytial Virus

  2002cites this paper
• Author Index to Volume 45 of Microbiology and Immunology

  2001cites this paper